Pharmaceutical company Square Pharma achieves a market capitalization of over Tk20,000 crores following nine months of operations.
Square Pharmaceuticals PLC, one of the leading pharmaceutical companies in Bangladesh, has once again surpassed the Tk20,000 crore market capitalisation mark after a nine-month gap. This significant milestone comes following an 11% surge in the company's share price since early July 2025, reaching Tk229.80.
The rebound in Square Pharmaceuticals' market cap was primarily driven by improved earnings and investment returns. The company's financial performance in the first half of 2025 showed a positive impact from increased investment income. Moreover, the company reported robust growth and profitability with revenue for the fiscal year 2025 (July–March) reaching Tk5,784.64 crore, an 11% increase, and profit amounting to Tk1,874.80 crore.
Square Pharmaceuticals PLC currently accounts for 5.59% of the Dhaka Stock Exchange's total market cap, making it the second-highest valued firm on the exchange. The company's strong fundamentals, including double-digit growth in both revenue and profit, have attracted the attention of various investors, including sponsors, directors, institutional investors, foreign investors, and the general public.
According to the latest shareholding disclosure (June 2025), sponsors and directors hold 43.59% of the company's shares, institutional investors 14.05%, foreign investors 15.14%, and the general public 27.22%. This distribution of shares reflects strong and stable shareholder confidence in the company.
The market capitalisation of Square Pharmaceuticals PLC has risen by Tk1,959 crore, reaching Tk20,370 crore. This growth was partially attributed to the spread of diseases during a challenging economic period marked by high inflation. As people were compelled to purchase medicines, Square Pharmaceuticals PLC was able to maintain its strong growth in revenue and profit.
However, the company did face a significant increase in expenditures for the purchase of raw materials due to inflation, as stated in the company's financial statement. Despite this challenge, Square Pharmaceuticals PLC was able to navigate these difficulties and continue its impressive growth trajectory.
Grameenphone, the top company by market capitalization at Tk42,224 crore, remains the leader on the Dhaka Stock Exchange. Despite this, Square Pharmaceuticals PLC's position in the total market cap has not been affected, demonstrating the company's resilience and potential for further growth.
For the January-March quarter of FY25, Square Pharmaceuticals PLC reported a revenue of Tk2,012.87 crore and a net profit of Tk605 crore, marking a 22% and 23% year-on-year increase, respectively. At the end of March, the company's earnings per share stood at Tk21.15, compared to Tk18.24 a year ago.
In summary, Square Pharmaceuticals PLC's rebound above Tk20,000 crore market capitalisation is a testament to the company's strong fundamentals and resilience in the face of economic challenges. With double-digit growth in both revenue and profit, and a strong investor base, Square Pharmaceuticals PLC continues to be a significant player in the Bangladeshi pharmaceutical industry.
The surge in Square Pharmaceuticals' share price and market capitalisation can be attributed to improved earnings and investment returns, as well as increased investment income.
With double-digit growth in both revenue and profit, and a strong investor base, Square Pharmaceuticals PLC is a significant player in the Bangladeshi business and investing landscape.
